OmniPathology Selects Gestalt as Digital Platform and Strategic Partner to Advance Innovation and Global Diagnostic Equity

SPOKANE, Wash., Oct. 1, 2025 /PRNewswire/ -- Gestalt, a leader in digital pathology and AI-driven laboratory solutions, is proud to announce that OmniPathology, a high-complexity independent pathology laboratory has selected their digital solution, PathFlow. This partnership marks a significant step forward in transforming diagnostic workflows through leading-edge technology, operational excellence, and a shared vision for global impact.

By integrating Gestalt's award-winning digital pathology platform with OmniPathology's advanced molecular and anatomic pathology services, the two organizations are setting a new standard for precision, scalability, and interoperability in laboratory diagnostics. The collaboration will streamline case management, accelerate turnaround times, and enhance diagnostic accuracy—delivering measurable improvements for clinicians and patients alike.

"At Gestalt, we believe innovation must be paired with purpose," said Lisa-Jean Clifford, President of Gestalt. "Our partnership with OmniPathology is not only about elevating laboratory performance—it's about laying the groundwork for diagnostic access in underserved communities around the world."

OmniPathology's commitment to excellence and patient-centric care aligns seamlessly with Gestalt's mission to modernize pathology through open, scalable platforms. Together, the organizations will explore initiatives aimed at extending digital diagnostic capabilities to regions with limited healthcare infrastructure, leveraging AI and cloud-based technologies as learning and teaching tools to bridge gaps in care.

"At OmniPathology, our commitment to innovation goes beyond adopting new tools. It's about shaping the future of diagnostics. Partnering with Gestalt allows us to combine their world-class AI capabilities with our best-in-class leadership in GI pathology, creating powerful synergies that will enhance precision, efficiency, and improve outcomes for patients," said Dr. Mohammad Kamal, Founder and CEO of OmniPathology."Together, we see tremendous opportunities to advance pathology, accelerate discoveries in clinical research, and make a meaningful impact on global health."

The partnership underscores both organizations' dedication to innovation, education access, and continuous improvement—setting the stage for broader industry adoption and meaningful global health outcomes.

About Gestalt  Gestalt transforms pathology through an intelligent, configurable, vendor-neutral, and AI-driven digital workflow that provides true interoperability enabling pathologists to diagnose diseases faster and more efficiently. Our PathFlow solution consists of professional, education, and research modules for ease of mixing and matching the digital needs of your facility in a single solution, freeing pathologists from tedious, repetitive, and manual tasks, allowing them to focus on their expertise – providing invaluable experience where it matters most. To learn more, visit www.gestaltdiagnostics.com and follow @Gestalt on LinkedIn

About OmniPathology OmniPathology is a leading gastrointestinal pathology and advanced molecular diagnostics laboratory based in Pasedena, Calif. The company delivers academic-level, state-of-the-art pathology services and cutting-edge molecular testing with expertise in infectious disease, cancer diagnostics, and proprietary assay development. Committed to innovation, quality, and precision, OmniPathology partners with clinicians worldwide to improve patient outcomes through accurate, timely, and advanced diagnostic solutions. Learn more at www.omnipathology.com 

SOURCE Gestalt Diagnostics